Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the ...
April 28 2021 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that two
trial in progress posters, on the Phase 1 INNATE clinical trial and
the Phase 2 SELECT clinical trial, will be presented at the
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
being held June 4-8, 2021.
Poster Details:
Poster Title: Phase 1, First-in-Human trial of
JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy
and in combination with anti-PD-1 in adult patients with advanced
solid tumors (INNATE)Presenter: Kyriakos P.
Papadopoulos, MD, South Texas Accelerated Research Therapeutics
(START), San Antonio, TXSession Title:
Developmental Therapeutics – ImmunotherapyAbstract
Number: TPS2672Date and Time: Friday,
June 4, 2021; 9:00am ET
Poster Title: Phase 2 Study of PD-1 Inhibitor
JTX-4014 (Pimivalimab) Alone and in Combination with Vopratelimab,
an ICOS Agonist, in Biomarker-selected Subjects with Metastatic
NSCLC After One Prior Platinum-containing Regimen
(SELECT)Presenter: Oleh Kobziev, MD, Regional
Center of Oncology, Kharkiv, 61070, UkraineSession
Title: Lung Cancer – Non-Small Cell
MetastaticAbstract Number: TPS9137Date and
Time: Friday, June 4, 2021; 9:00am ET
About JTX-8064
JTX-8064 is a humanized IgG4 monoclonal antibody designed to
specifically bind to Leukocyte Immunoglobulin Like Receptor B2
(LILRB2/ILT4) and block interactions with its ligands. JTX-8064 is
the first tumor-associated macrophage candidate developed from
Jounce’s Translational Science Platform. Preclinical data presented
at the 2020 Society for Immunotherapy of Cancer’s Annual
Meeting and the 2019 and 2021 American Association for Cancer
Research Annual Meetings support the development of JTX-8064
as a novel immunotherapy to reprogram immune-suppressive
macrophages and enhance anti-tumor immunity. A Phase 1 clinical
trial named INNATE (NCT04669899), of JTX-8064 as a monotherapy and
in combination with either Jounce’s internal anti-PD-1 inhibitor,
pimivalimab (formerly JTX-4014), or an approved anti-PD-1
inhibitor, is currently enrolling patients with advanced solid
tumors.
About Pimivalimab
Pimivalimab (formerly JTX-4014) is a well-characterized fully
human IgG4 monoclonal antibody designed to block binding to PD-L1
and PD-L2. Pimivalimab demonstrated a 17% durable overall response
rate in a Phase 1 trial of 18 heavily pre-treated PD-(L)1 inhibitor
naïve patients, which excluded all tumor types for which PD-(L)1
inhibitors were approved. In this Phase 1 trial, pimivalimab was
shown to have an acceptable safety profile. Pimivalimab is
currently being assessed in the INNATE Phase 1 trial (NCT04669899)
in combination with JTX-8064, a LILRB2 (ILT4) inhibitor.
Pimivalimab is also being assessed in the SELECT Phase 2 clinical
trial (NCT04549025) in combination with vopratelimab, a
clinical-stage monoclonal antibody that binds to and activates
ICOS, the Inducible T cell CO-Stimulator, a protein on the surface
of certain T cells commonly found in many solid tumors. The SELECT
trial compares vopratelimab plus pimivalimab to pimivalimab alone
in immunotherapy naïve NSCLC patients who have been pre-selected
with the TISvopra predictive biomarker, an 18 gene RNA tumor
inflammation signature which predicted the emergence of ICOS hi CD4
T cells and clinical benefit in the ICONIC trial of vopratelimab
alone and in combination with a PD-1 inhibitor.
About Vopratelimab
Vopratelimab is a clinical-stage monoclonal antibody that binds
to and activates ICOS, the Inducible T cell CO-Stimulator, a
protein on the surface of certain T cells commonly found in many
solid tumors. Vopratelimab is currently being assessed in the
SELECT Phase 2 clinical trial (NCT04549025) in combination with
Jounce’s internal investigational PD-1 inhibitor, pimivalimab
(formerly JTX-4014), compared to pimivalimab alone. The SELECT
trial is currently enrolling approximately 75 immunotherapy naïve
NSCLC patients who have been pre-selected with the
TISvopra predictive biomarker, an 18 gene RNA tumor
inflammation signature which predicted the emergence of ICOS hi CD4
T cells and clinical benefit in the ICONIC trial of vopratelimab
alone and in combination with a PD-1 inhibitor. SELECT is powered
to demonstrate the statistical superiority of the combination of
vopratelimab plus pimivalimab compared to pimivalimab.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy
company dedicated to transforming the treatment of cancer by
developing therapies that enable the immune system to attack tumors
and provide long-lasting benefits to patients through a
biomarker-driven approach. Jounce currently has multiple
development stage programs ongoing while simultaneously advancing
additional early-stage assets from its robust discovery engine
based on its Translational Science Platform. Jounce’s highest
priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist
shown to reprogram immune-suppressive tumor associated macrophages
to an anti-tumor state in preclinical studies. A Phase 1 clinical
trial, named INNATE, of JTX-8064 as a monotherapy and in
combination with pimivalimab (formerly JTX-4014), Jounce’s internal
PD-1 inhibitor, or pembrolizumab is currently enrolling patients
with advanced solid tumors. Jounce’s most advanced product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS, and is currently being studied in the SELECT Phase
2 trial. Pimivalimab is a PD-1 inhibitor intended for combination
use in the INNATE and SELECT trials and with Jounce’s broader
pipeline. Additionally, Jounce exclusively licensed worldwide
rights to JTX-1811, a monoclonal antibody targeting CCR8 and
designed to selectively deplete T regulatory cells in the tumor
microenvironment, to Gilead Sciences, Inc. For more information,
please visit www.jouncetx.com.
Investor and Media Contacts:Mark YoreJounce
Therapeutics, Inc.+1-857-200-1255 myore@jouncetx.com
Malin DeonJounce Therapeutics,
Inc.+1-857-259-3843mdeon@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024